The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study

被引：7

作者：

Sia, Tiffany Y. ^{[1
]}

Tew, William P. ^{[1
,19
]}

Purdy, Christopher ^{[2
]}

Chi, Dennis S. ^{[1
]}

Menzin, Andrew W. ^{[3
]}

Lovecchio, John L. ^{[3
]}

Bookman, Michael A. ^{[4
]}

Cohn, David E. ^{[5
]}

Teoh, Deanna G. ^{[6
]}

Friedlander, Michael ^{[7
,8
]}

Bender, David ^{[9
]}

Mutch, David G. ^{[10
]}

Gershenson, David M. ^{[11
]}

Tewari, Krishnansu S. ^{[12
]}

Wenham, Robert M. ^{[13
]}

Hendrickson, Andrea E. Wahner ^{[14
]}

Lee, Roger B. ^{[15
]}

Gray, Heidi J. ^{[16
]}

Secord, Angeles Alvarez ^{[17
]}

Van Le, Linda ^{[18
]}

Lichtman, Stuart M.

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[3] North Shore Long Isl Jewish Med Ctr, Manhasset, NY USA

[4] Kaiser Permanente, Gynecol Oncol Therapeut, San Francisco, CA USA

[5] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[6] Univ Minnesota, Med Ctr, Minneapolis, MN USA

[7] UNSW, Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia

[8] UNSW, Prince Wales Clin Sch, Sydney, NSW, Australia

[9] Univ Iowa Hosp, Iowa City, IA USA

[10] Washington Univ, St Louis, MO USA

[11] MD Anderson Canc Ctr, Houston, TX USA

[12] Univ Calif Irvine, Orange, CA USA

[13] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[14] Mayo Clin, Rochester, MN USA

[15] Tacoma Gen Hosp, Tacoma, WA USA

[16] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[17] Duke Univ, Med Ctr, Durham, NC USA

[18] Univ N Carolina, Chapel Hill, NC USA

[19] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA

来源：

GYNECOLOGIC ONCOLOGY | 2023年 / 173卷

关键词：

PHASE-III TRIAL; INTERGROUP TRIAL; PLUS BEVACIZUMAB; ELDERLY-PATIENTS; STAGE-III; PACLITAXEL; CISPLATIN; FRAILTY; CARBOPLATIN; SURVIVAL;

D O I：

10.1016/j.ygyno.2023.03.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Results. We included a total of 3686 patients, with 620 patients (16.8%) >= 70 years. OS was 37.2 months in older compared to 45.0 months in younger patients (HR 1.21, 95% CI, 1.09-1.34, p < 0.001). Older patients had an increased risk of cancer-specific-death (HR 1.16, 95% CI, 1.04-1.29) as well as non-cancer related deaths (HR 2.78, 95% CI, 2.00-3.87). Median PFS was 15.1 months in older compared to 16.0 months in younger patients (HR 1.10, 95% CI, 1.00-1.20, p = 0.056). In the carboplatin/paclitaxel arm, older patients were just as likely to complete therapy and more likely to develop grade >= 2 peripheral neuropathy (35.7 vs 19.7%, p < 0.001). Risk of other toxicities remained equal between groups. Conclusions. In women with advanced EOC receiving chemotherapy, age >= 70 was associated with shorter OS and cancer specific survival. Older patients receiving carboplatin and paclitaxel reported higher rates of grade >= 2 neuropathy but were not more likely to suffer from other chemotherapy related toxicities. Clintrials.gov: NCT00011986 (c) 2023 Elsevier Inc. All rights reserved.

引用

页码：130 / 137

页数：8

共 37 条

[1] How long should first-line chemotherapy continue? [J].